{"id":"https://openalex.org/W71454341","doi":null,"title":"[Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].","display_name":"[Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].","publication_year":2003,"publication_date":"2003-01-01","ids":{"openalex":"https://openalex.org/W71454341","mag":"71454341","pmid":"https://pubmed.ncbi.nlm.nih.gov/14598513"},"language":"ru","primary_location":{"id":"pmid:14598513","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14598513","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vestnik Rossiiskoi akademii meditsinskikh nauk","raw_type":"Clinical Trial"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"A Ia Grinenko","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Ia Grinenko","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113768087","display_name":"E M Krupitski\u012d","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E M Krupitski\u012d","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5028959450","display_name":"Edwin E. Zvartau","orcid":"https://orcid.org/0000-0002-3597-7482","observed_orcids":["https://orcid.org/0000-0002-3597-7482"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E E Zvartau","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3383,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.64526339,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":96},"biblio":{"volume":null,"issue":"10","first_page":"54","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.9330999851226807,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.9330999851226807,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.06109999865293503,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/heroin-dependence","display_name":"heroin addiction","score":0.9980000257492065},{"id":"https://openalex.org/keywords/opioid-use-disorder","display_name":"opioid use disorder","score":0.6240000128746033},{"id":"https://openalex.org/keywords/anhedonia","display_name":"anhedonia","score":0.8410000205039978},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.9129999876022339},{"id":"https://openalex.org/keywords/naltrexone","display_name":"naltrexone","score":0.9750000238418579},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.8999999761581421},{"id":"https://openalex.org/keywords/citalopram","display_name":"citalopram","score":0.9950000047683716},{"id":"https://openalex.org/keywords/memantine","display_name":"memantine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.890999972820282},{"id":"https://openalex.org/keywords/antidepressants","display_name":"antidepressants","score":0.7979999780654907},{"id":"https://openalex.org/keywords/opioid-receptor-antagonism","display_name":"opioid antagonism","score":0.6520000100135803},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.6940000057220459}],"concepts":[{"id":"https://openalex.org/C2778941446","wikidata":"https://www.wikidata.org/wiki/Q545365","display_name":"Anhedonia","level":3,"score":0.836953341960907},{"id":"https://openalex.org/C2777972943","wikidata":"https://www.wikidata.org/wiki/Q409587","display_name":"Naltrexone","level":4,"score":0.7479994297027588},{"id":"https://openalex.org/C2781089641","wikidata":"https://www.wikidata.org/wiki/Q7310684","display_name":"Relapse prevention","level":2,"score":0.5570347905158997},{"id":"https://openalex.org/C2779541405","wikidata":"https://www.wikidata.org/wiki/Q498902","display_name":"Craving","level":3,"score":0.5469586253166199},{"id":"https://openalex.org/C2778903686","wikidata":"https://www.wikidata.org/wiki/Q60168","display_name":"Heroin","level":3,"score":0.5302737951278687},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.5211265683174133},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4962168335914612},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4952675402164459},{"id":"https://openalex.org/C48856860","wikidata":"https://www.wikidata.org/wiki/Q12029","display_name":"Addiction","level":2,"score":0.4748915731906891},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.44373390078544617},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.34989166259765625},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3280470371246338},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2897941470146179},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.25004565715789795},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.231818288564682},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.15192025899887085},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09609800577163696}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000639","descriptor_name":"Amitriptyline","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000639","descriptor_name":"Amitriptyline","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000704","descriptor_name":"Analysis of Variance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000929","descriptor_name":"Antidepressive Agents, Tricyclic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000929","descriptor_name":"Antidepressive Agents, Tricyclic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006556","descriptor_name":"Heroin Dependence","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006556","descriptor_name":"Heroin Dependence","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009271","descriptor_name":"Naltrexone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013375","descriptor_name":"Substance Withdrawal Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013375","descriptor_name":"Substance Withdrawal Syndrome","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":true},{"descriptor_ui":"D015283","descriptor_name":"Citalopram","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015283","descriptor_name":"Citalopram","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019964","descriptor_name":"Mood Disorders","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D019964","descriptor_name":"Mood Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:14598513","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14598513","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Vestnik Rossiiskoi akademii meditsinskikh nauk","raw_type":"Clinical Trial"},{"id":"mag:71454341","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14598513","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2088797296","https://openalex.org/W1972418383","https://openalex.org/W2993205759","https://openalex.org/W2376859414","https://openalex.org/W2341652507","https://openalex.org/W2378835004","https://openalex.org/W2079969215","https://openalex.org/W2356737430","https://openalex.org/W2329845653","https://openalex.org/W2132002674"],"abstract_inverted_index":{"After":[0],"withdrawal":[1],"arrest":[2,105],"in":[3,33,44,60,129,162],"many":[4],"heroin":[5,55,163,195],"addicts,":[6],"they":[7],"displayed":[8],"the":[9,29,57,64,75,132,166,169,176,181,194,199,207,212],"syndrome":[10],"of":[11,67,110,135,158,191],"anhedonia":[12,177,208],"including":[13],"affective":[14],"disorders":[15],"(depression,":[16],"dysphoria,":[17],"anxiety),":[18],"dyssomnia":[19],"and":[20,47,52,81,86,95,197,210,217,228],"a":[21,91,154,184,189,221],"pathologic":[22],"craving":[23],"for":[24,31,54],"opiates.":[25],"Anhedonia":[26],"is":[27,40,220],"often":[28],"cause":[30],"recurrence":[32,45,200,229],"heroine":[34,142],"addiction,":[35],"therefore,":[36],"an":[37,41,96],"appropriate":[38],"treatment":[39],"important":[42],"aspect":[43],"prevention":[46],"remission":[48,116,130,218,226],"stabilization.":[49],"Since":[50],"depression":[51],"drive":[53],"are":[56],"key":[58],"symptoms":[59,209],"anhedonia,":[61,111],"we":[62],"undertook":[63],"efficiency":[65],"study":[66],"therapy":[68,186],"(in":[69],"anhedonia)":[70],"by":[71,150],"antidepressants":[72,204],"belonging":[73],"to":[74,104,123,127,225],"selective":[76],"serotonin":[77],"reuptake":[78],"inhibitors":[79],"(SSRI)":[80],"NMDA":[82],"receptor":[83],"antagonists,":[84],"citalopram":[85],"memantine,":[87],"respectively,":[88],"which":[89,179],"have":[90],"clinical":[92],"antidepressant":[93],"action":[94,114,196],"experimental":[97],"anti-addictive":[98],"action.":[99],"Both":[100],"drugs":[101],"were":[102],"found":[103],"effectively":[106],"virtually":[107],"all":[108,141],"signs":[109],"however,":[112],"their":[113],"on":[115,175],"stabilization":[117,227],"was":[118],"rather":[119],"moderate.":[120],"It":[121],"looked":[122],"be":[124],"more":[125],"promising":[126,223],"use,":[128],"stabilization,":[131],"uttermost":[133],"antagonist":[134],"opiate":[136],"receptors":[137],"(naltrexone)":[138],"blocking":[139],"reliably":[140],"effects.":[143],"A":[144],"double":[145],"blind":[146],"placebo-controlled":[147],"study,":[148],"undertaken":[149],"us,":[151],"convincingly":[152],"showed":[153],"significantly":[155],"smaller":[156],"number":[157],"relapses":[159],"with":[160,202,214],"naltrexone":[161,192,215],"addicts.":[164],"At":[165],"same":[167],"time,":[168],"drug":[170],"had":[171],"no":[172],"valuable":[173],"effect":[174],"symptoms,":[178],"worsened":[180],"compliance":[182,213],"entailing":[183],"poorer":[185],"efficiency.":[187],"Finally,":[188],"combination":[190],"(blocking":[193],"reducing":[198],"rate)":[201],"SSRI":[203],"(effectively":[205],"arresting":[206],"improving":[211],"medication":[216],"quality)":[219],"most":[222],"approach":[224],"prevention.":[230]},"counts_by_year":[{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}